{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:30:23Z","timestamp":1791725423732,"version":"4.3.4"},"reference-count":146,"publisher":"China Science Publishing & Media Ltd.","issue":"1","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2026,1,1]]},"DOI":"10.3724\/abbs.2025235","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:30:40Z","timestamp":1765276240000},"page":"49-66","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Immune checkpoint TIM-3 in tumor immunotherapy"],"prefix":"10.3724","volume":"58","author":[{"given":"Shuaiya","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","volume":"11","author":"Wolchok JD","year":"2010","unstructured":"Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol, 2010, 11: 155-164.","journal-title":"Lancet Oncol"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"Hodi FS","year":"2010","unstructured":"Hodi FS, O\u2032Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010, 363: 711-723.","journal-title":"N Engl J Med"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"e967147","DOI":"10.4161\/21624011.2014.967147","volume":"3","author":"Galluzzi L","year":"2014","unstructured":"Galluzzi L, Kroemer G, Eggermont A. Novel immune checkpoint blocker approved for the treatment of advanced melanoma. OncoImmunology, 2014, 3: e967147.","journal-title":"OncoImmunology"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","volume":"30","author":"He X","year":"2020","unstructured":"He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res, 2020, 30: 660-669.","journal-title":"Cell Res"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/415536a","volume":"415","author":"Monney L","year":"2002","unstructured":"Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature, 2002, 415: 536-541.","journal-title":"Nature"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","volume":"119","author":"Ndhlovu LC","year":"2012","unstructured":"Ndhlovu LC, Lopez-Verg\u00e8s S, Barbour JD, Jones RB, Jha AR, Long BR, Schoeffler EC. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood, 2012, 119: 3734-3743.","journal-title":"Blood"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1002\/eji.200939274","volume":"39","author":"Hastings WD","year":"2009","unstructured":"Hastings WD, Anderson DE, Kassam N, Koguchi K, Greenfield EA, Kent SC, Zheng XX. TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J Immunol, 2009, 39: 2492-2501.","journal-title":"Eur J Immunol"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3390\/cells11060964","volume":"11","author":"Weimer P","year":"2022","unstructured":"Weimer P, Wellbrock J, Sturmheit T, Oliveira-Ferrer L, Ding Y, Menzel S, Witt M. Tissue-specific expression of TIGIT, PD-1, TIM-3, and CD39 by \u03b3\u03b4 T cells in ovarian cancer. Cells, 2022, 11: 964.","journal-title":"Cells"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"111719","DOI":"10.1016\/j.yexcr.2019.111719","volume":"386","author":"Li X","year":"2020","unstructured":"Li X, Lu H, Gu Y, Zhang X, Zhang G, Shi T, Chen W. Tim-3 suppresses the killing effect of V\u03b39V\u03b42 T cells on colon cancer cells by reducing perforin and granzyme B expression. Exp Cell Res, 2020, 386: 111719.","journal-title":"Exp Cell Res"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41590-023-01448-7","volume":"24","author":"Rancan C","year":"2023","unstructured":"Rancan C, Arias-Badia M, Dogra P, Chen B, Aran D, Yang H, Luong D. Exhausted intratumoral V\u03b42-\u03b3\u03b4 T cells in human kidney cancer retain effector function. Nat Immunol, 2023, 24: 612-624.","journal-title":"Nat Immunol"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"e20211431","DOI":"10.1084\/jem.20211431","volume":"220","author":"Edwards SC","year":"2023","unstructured":"Edwards SC, Hedley A, Hoevenaar WHM, Wiesheu R, Glauner T, Kilbey A, Shaw R. PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A-producing \u03b3\u03b4 T cells. J Exp Med, 2023, 220: e20211431.","journal-title":"J Exp Med"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"e23849","DOI":"10.4161\/onci.23849","volume":"2","author":"Sakuishi K","year":"2013","unstructured":"Sakuishi K, Ngiow SF, Sullivan JM, Teng MWL, Kuchroo VK, Smyth MJ, Anderson AC. TIM3+ FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. OncoImmunology, 2013, 2: e23849.","journal-title":"OncoImmunology"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/ni.2376","volume":"13","author":"Chiba S","year":"2012","unstructured":"Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Fujioka Y. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol, 2012, 13: 832-842.","journal-title":"Nat Immunol"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/sj.jid.5700616","volume":"127","author":"Wiener Z","year":"2007","unstructured":"Wiener Z, Kohalmi B, Pocza P, Jeager J, Tolgyesi G, Toth S, Gorbe E. TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Investig Dermatol, 2007, 127: 906-914.","journal-title":"J Investig Dermatol"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nri1111","volume":"3","author":"Kuchroo VK","year":"2003","unstructured":"Kuchroo VK, Umetsu DT, DeKruyff RH, Freeman GJ. The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol, 2003, 3: 454-462.","journal-title":"Nat Rev Immunol"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3390\/ijms18030645","volume":"18","author":"Du W","year":"2017","unstructured":"Du W, Yang M, Turner A, Xu C, Ferris R, Huang J, Kane L. TIM-3 as a target for cancer immunotherapy and mechanisms of action. Int J Mol Sci, 2017, 18: 645.","journal-title":"Int J Mol Sci"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"Anderson AC","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity, 2016, 44: 989-1004.","journal-title":"Immunity"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"Zhu C","year":"2005","unstructured":"Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol, 2005, 6: 1245-1252.","journal-title":"Nat Immunol"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.4049\/jimmunol.0903275","volume":"185","author":"Dardalhon V","year":"2010","unstructured":"Dardalhon V, Anderson AC, Karman J, Apetoh L, Chandwaskar R, Lee DH, Cornejo M. Tim-3\/Galectin-9 Pathway: regulation of Th1 Immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol, 2010, 185: 1383-1392.","journal-title":"J Immunol"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nature13848","volume":"517","author":"Huang YH","year":"2015","unstructured":"Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, Dougan SK. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature, 2015, 517: 386-390.","journal-title":"Nature"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"Sakuishi K","year":"2010","unstructured":"Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med, 2010, 207: 2187-2194.","journal-title":"J Exp Med"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/1078-0432.CCR-15-1535","volume":"23","author":"Kim JE","year":"2017","unstructured":"Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, Liu A. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res, 2017, 23: 124-136.","journal-title":"Clin Cancer Res"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/ni739","volume":"2","author":"McIntire JJ","year":"2001","unstructured":"McIntire JJ, Umetsu SE, Akbari O, Potter M, Kuchroo VK, Barsh GS, Freeman GJ. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol, 2001, 2: 1109-1116.","journal-title":"Nat Immunol"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.4049\/jimmunol.0903059","volume":"184","author":"DeKruyff RH","year":"2010","unstructured":"DeKruyff RH, Bu X, Ballesteros A, Santiago C, Chim YLE, Lee HH, Karisola P. T cell\/transmembrane, Ig, and Mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol, 2010, 184: 1918-1930.","journal-title":"J Immunol"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jhep.2009.12.005","volume":"52","author":"Ju Y","year":"2010","unstructured":"Ju Y, Hou N, Meng J, Wang X, Zhang X, Zhao D, Liu Y. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol, 2010, 52: 322-329.","journal-title":"J Hepatol"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1136\/gutjnl-2014-307671","volume":"64","author":"Yan W","year":"2015","unstructured":"Yan W, Liu X, Ma H, Zhang H, Song X, Gao L, Liang X. Tim-3 fosters HCC development by enhancing TGF-\u03b2-mediated alternative activation of macrophages. Gut, 2015, 64: 1593-1604.","journal-title":"Gut"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"Im SJ","year":"2016","unstructured":"Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature, 2016, 537: 417-421.","journal-title":"Nature"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ccell.2017.11.019","volume":"33","author":"de Mingo Pulido \u00c1","year":"2018","unstructured":"de Mingo Pulido \u00c1, Gardner A, Hiebler S, Soliman H, Rugo HS, Krummel MF, Coussens LM. TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer. Cancer Cell, 2018, 33: 60-74.e6.","journal-title":"Cancer Cell"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","volume":"595","author":"Dixon KO","year":"2021","unstructured":"Dixon KO, Tabaka M, Schramm MA, Xiao S, Tang R, Dionne D, Anderson AC. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature, 2021, 595: 101-106.","journal-title":"Nature"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1007\/s00262-023-03516-1","volume":"72","author":"Sauer N","year":"2023","unstructured":"Sauer N, Janicka N, Szlasa W, Skinderowicz B, Ko\u0142odzi\u0144ska K, Dwernicka W, O\u015bliz\u0142o M. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors. Cancer Immunol Immunother, 2023, 72: 3405-3425.","journal-title":"Cancer Immunol Immunother"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41586-025-08852-z","volume":"641","author":"Kimura K","year":"2025","unstructured":"Kimura K, Subramanian A, Yin Z, Khalilnezhad A, Wu Y, He D, Dixon KO. Immune checkpoint TIM-3 regulates microglia and Alzheimer\u2019s disease. Nature, 2025, 641: 718-731.","journal-title":"Nature"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Wolf Y","year":"2020","unstructured":"Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol, 2020, 20: 173-185.","journal-title":"Nat Rev Immunol"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.canlet.2021.04.011","volume":"510","author":"Kandel S","year":"2021","unstructured":"Kandel S, Adhikary P, Li G, Cheng K. The TIM3\/Gal9 signaling pathway: an emerging target for cancer immunotherapy. Cancer Lett, 2021, 510: 67-78.","journal-title":"Cancer Lett"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.bbrc.2006.10.079","volume":"351","author":"van de Weyer PS","year":"2006","unstructured":"van de Weyer PS, Muehlfeit M, Klose C, Bonventre JV, Walz G, Kuehn EW. A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9. Biochem Biophys Res Commun, 2006, 351: 571-576.","journal-title":"Biochem Biophys Res Commun"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12520","volume":"276","author":"Das M","year":"2017","unstructured":"Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev, 2017, 276: 97-111.","journal-title":"Immunol Rev"},{"key":"CITATION36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.immuni.2007.01.016","volume":"26","author":"Cao E","year":"2007","unstructured":"Cao E, Zang X, Ramagopal UA, Mukhopadhaya A, Fedorov A, Fedorov E, Zencheck WD. T cell immunoglobulin Mucin-3 crystal structure reveals a Galectin-9-independent ligand-binding surface. Immunity, 2007, 26: 311-321.","journal-title":"Immunity"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.immuni.2007.01.014","volume":"26","author":"Santiago C","year":"2007","unstructured":"Santiago C, Ballesteros A, Tami C, Mart\u00ednez-Mu\u00f1oz L, Kaplan GG, Casasnovas JM. Structures of T cell immunoglobulin mucin receptors 1 and 2 reveal mechanisms for regulation of immune responses by the TIM receptor family. Immunity, 2007, 26: 299-310.","journal-title":"Immunity"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"17512","DOI":"10.1038\/s41598-018-35754-0","volume":"8","author":"Gandhi AK","year":"2018","unstructured":"Gandhi AK, Kim WM, Sun ZYJ, Huang YH, Bonsor DA, Sundberg EJ, Kondo Y. High resolution X-ray and NMR structural study of human T-cell immunoglobulin and mucin domain containing protein-3. Sci Rep, 2018, 8: 17512.","journal-title":"Sci Rep"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/nm.2871","volume":"18","author":"Rangachari M","year":"2012","unstructured":"Rangachari M, Zhu C, Sakuishi K, Xiao S, Karman J, Chen A, Angin M. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3\u2013mediated cell death and exhaustion. Nat Med, 2012, 18: 1394-1400.","journal-title":"Nat Med"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1128\/MCB.05297-11","volume":"31","author":"Lee J","year":"2011","unstructured":"Lee J, Su EW, Zhu C, Hainline S, Phuah J, Moroco JA, Smithgall TE. Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways. Mol Cell Biol, 2011, 31: 3963-3974.","journal-title":"Mol Cell Biol"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/ni988","volume":"4","author":"Sabatos CA","year":"2003","unstructured":"Sabatos CA, Chakravarti S, Cha E, Schubart A, S\u00e1nchez-Fueyo A, Zheng XX, Coyle AJ. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol, 2003, 4: 1102-1110.","journal-title":"Nat Immunol"},{"key":"CITATION42","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.4049\/jimmunol.176.3.1411","volume":"176","author":"Geng H","year":"2006","unstructured":"Geng H, Zhang GM, Li D, Zhang H, Yuan Y, Zhu HG, Xiao H. Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response. J Immunol, 2006, 176: 1411-1420.","journal-title":"J Immunol"},{"key":"CITATION43","doi-asserted-by":"publisher","first-page":"34529","DOI":"10.1074\/jbc.M113.488478","volume":"288","author":"M\u00f6ller-Hackbarth K","year":"2013","unstructured":"M\u00f6ller-Hackbarth K, Dewitz C, Schweigert O, Trad A, Garbers C, Rose-John S, Scheller J. A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (Tim-3). J Biol Chem, 2013, 288: 34529-34544.","journal-title":"J Biol Chem"},{"key":"CITATION44","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1128\/JVI.00006-15","volume":"89","author":"Clayton KL","year":"2015","unstructured":"Clayton KL, Douglas-Vail MB, Rahman AKMN, Medcalf KE, Xie IY, Chew GM, Tandon R. Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression. J Virol, 2015, 89: 3723-3736.","journal-title":"J Virol"},{"key":"CITATION45","doi-asserted-by":"crossref","unstructured":"Conde-Rodr\u00edguez I, P\u00e9rez-Picazo S, V\u00e1zquez-Zamora VJ, Reyes-Leyva J, Vallejo-Ruiz V. Serum soluble Tim-3 is elevated in patients with cervical cancer and is higher in advanced clinical stages.  Biomedical reports  2025, 22: 90.","DOI":"10.3892\/br.2025.1968"},{"key":"CITATION46","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13046-025-03293-y","volume":"44","author":"Pourmir I","year":"2025","unstructured":"Pourmir I, Benhamouda N, Tran T, Roux H, Pineau J, Gey A, Munoz A. Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma. J Exp Clin Cancer Res, 2025, 44: 54.","journal-title":"J Exp Clin Cancer Res"},{"key":"CITATION47","doi-asserted-by":"publisher","first-page":"101686","DOI":"10.1016\/j.xcrm.2024.101686","volume":"5","author":"Chen C","year":"2024","unstructured":"Chen C, Zhao F, Peng J, Zhao D, Xu L, Li H, Ma S. Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance. Cell Rep Med, 2024, 5: 101686.","journal-title":"Cell Rep Med"},{"key":"CITATION48","doi-asserted-by":"publisher","first-page":"782","DOI":"10.4049\/jimmunol.1302663","volume":"192","author":"Clayton KL","year":"2014","unstructured":"Clayton KL, Haaland MS, Douglas-Vail MB, Mujib S, Chew GM, Ndhlovu LC, Ostrowski MA. T Cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases. J Immunol, 2014, 192: 782-791.","journal-title":"J Immunol"},{"key":"CITATION49","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1084\/jem.20100637","volume":"207","author":"Fourcade J","year":"2010","unstructured":"Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med, 2010, 207: 2175-2186.","journal-title":"J Exp Med"},{"key":"CITATION50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.molimm.2013.11.001","volume":"58","author":"Ju Y","year":"2014","unstructured":"Ju Y, Shang X, Liu Z, Zhang J, Li Y, Shen Y, Liu Y. The Tim-3\/galectin-9 pathway involves in the homeostasis of hepatic Tregs in a mouse model of concanavalin A-induced hepatitis. Mol Immunol, 2014, 58: 85-91.","journal-title":"Mol Immunol"},{"key":"CITATION51","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2011-06-360321","volume":"119","author":"Gleason MK","year":"2012","unstructured":"Gleason MK, Lenvik TR, McCullar V, Felices M, O\u2032Brien MS, Cooley SA, Verneris MR. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood, 2012, 119: 3064-3072.","journal-title":"Blood"},{"key":"CITATION52","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1084\/jem.20100687","volume":"207","author":"Jayaraman P","year":"2010","unstructured":"Jayaraman P, Sada-Ovalle I, Beladi S, Anderson AC, Dardalhon V, Hotta C, Kuchroo VK. Tim3 binding to galectin-9 stimulates antimicrobial immunity. J Exp Med, 2010, 207: 2343-2354.","journal-title":"J Exp Med"},{"key":"CITATION53","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1126\/science.1148536","volume":"318","author":"Anderson AC","year":"2007","unstructured":"Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, Chandwaskar R. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science, 2007, 318: 1141-1143.","journal-title":"Science"},{"key":"CITATION54","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/imm.13488","volume":"168","author":"Yu S","year":"2023","unstructured":"Yu S, Ren X, Meng F, Guo X, Tao J, Zhang W, Liu Z. TIM3\/CEACAM1 pathway involves in myeloid-derived suppressor cells induced CD8+ T cells exhaustion and bone marrow inflammatory microenvironment in myelodysplastic syndrome. Immunology, 2023, 168: 273-289.","journal-title":"Immunology"},{"key":"CITATION55","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1038\/sj.onc.1209541","volume":"25","author":"Leung N","year":"2006","unstructured":"Leung N, Turbide C, Olson M, Marcus V, Jothy S, Beauchemin N. Deletion of the carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1) gene contributes to colon tumor progression in a murine model of carcinogenesis. Oncogene, 2006, 25: 5527-5536.","journal-title":"Oncogene"},{"key":"CITATION56","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.immuni.2007.11.011","volume":"27","author":"Kobayashi N","year":"2007","unstructured":"Kobayashi N, Karisola P, Pe\u00f1a-Cruz V, Dorfman DM, Jinushi M, Umetsu SE, Butte MJ. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity, 2007, 27: 927-940.","journal-title":"Immunity"},{"key":"CITATION57","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1182\/blood-2008-10-185884","volume":"113","author":"Nakayama M","year":"2009","unstructured":"Nakayama M, Akiba H, Takeda K, Kojima Y, Hashiguchi M, Azuma M, Yagita H. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood, 2009, 113: 3821-3830.","journal-title":"Blood"},{"key":"CITATION58","doi-asserted-by":"publisher","first-page":"e152864","DOI":"10.1172\/JCI152864","volume":"132","author":"Pagliano O","year":"2022","unstructured":"Pagliano O, Morrison RM, Chauvin JM, Banerjee H, Davar D, Ding Q, Tanegashima T. Tim-3 mediates T cell trogocytosis to limit antitumor immunity. J Clin Invest, 2022, 132: e152864.","journal-title":"J Clin Invest"},{"key":"CITATION59","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1158\/0008-5472.CAN-19-2332","volume":"80","author":"Tan S","year":"2020","unstructured":"Tan S, Xu Y, Wang Z, Wang T, Du X, Song X, Guo X. Tim-3 hampers tumor surveillance of liver-resident and conventional NK cells by disrupting PI3K signaling. Cancer Res, 2020, 80: 1130-1142.","journal-title":"Cancer Res"},{"key":"CITATION60","doi-asserted-by":"publisher","first-page":"e1385690","DOI":"10.1080\/2162402X.2017.1385690","volume":"7","author":"Sabatos-Peyton CA","year":"2018","unstructured":"Sabatos-Peyton CA, Nevin J, Brock A, Venable JD, Tan DJ, Kassam N, Xu F. Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy. OncoImmunology, 2018, 7: e1385690.","journal-title":"OncoImmunology"},{"key":"CITATION61","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s12276-022-00736-w","volume":"54","author":"Chen R","year":"2022","unstructured":"Chen R, Kang R, Tang D. The mechanism of HMGB1 secretion and release. Exp Mol Med, 2022, 54: 91-102.","journal-title":"Exp Mol Med"},{"key":"CITATION62","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/hep.26938","volume":"59","author":"Dolina JS","year":"2014","unstructured":"Dolina JS, Braciale TJ, Hahn YS. Liver-primed CD8+ T cells suppress antiviral adaptive immunity through galectin-9-independent T-cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice. Hepatology, 2014, 59: 1351-1365.","journal-title":"Hepatology"},{"key":"CITATION63","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ymthe.2021.11.015","volume":"30","author":"Wang T","year":"2022","unstructured":"Wang T, Zhang J, Li N, Li M, Ma S, Tan S, Guo X. Spatial distribution and functional analysis define the action pathway of Tim-3\/Tim-3 ligands in tumor development. Mol Ther, 2022, 30: 1135-1148.","journal-title":"Mol Ther"},{"key":"CITATION64","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.1073\/pnas.94.11.5744","volume":"94","author":"Huard B","year":"1997","unstructured":"Huard B, Mastrangeli R, Prigent P, Bruniquel D, Donini S, El-Tayar N, Maigret B. Characterization of the major histocompatibility complex class II binding site on LAG-3\u2009protein. Proc Natl Acad Sci USA, 1997, 94: 5744-5749.","journal-title":"Proc Natl Acad Sci USA"},{"key":"CITATION65","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"Woo SR","year":"2012","unstructured":"Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res, 2012, 72: 917-927.","journal-title":"Cancer Res"},{"key":"CITATION66","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1073\/pnas.1003345107","volume":"107","author":"Matsuzaki J","year":"2010","unstructured":"Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA, 2010, 107: 7875-7880.","journal-title":"Proc Natl Acad Sci USA"},{"key":"CITATION67","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12032-014-0082-9","volume":"31","author":"Chen J","year":"2014","unstructured":"Chen J, Chen Z. The effect of immune microenvironment on the progression and prognosis of colorectal cancer. Med Oncol, 2014, 31: 82.","journal-title":"Med Oncol"},{"key":"CITATION68","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"Yu X","year":"2009","unstructured":"Yu X, Harden K, C Gonzalez L, Francesco M, Chiang E, Irving B, Tom I. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol, 2009, 10: 48-57.","journal-title":"Nat Immunol"},{"key":"CITATION69","doi-asserted-by":"publisher","first-page":"e1348","DOI":"10.1002\/cti2.1348","volume":"10","author":"Holder KA","year":"2021","unstructured":"Holder KA, Burt K, Grant MD. TIGIT blockade enhances NK cell activity against autologous HIV-1-infected CD4+ T cells. Clin & Trans Imm, 2021, 10: e1348.","journal-title":"Clin & Trans Imm"},{"key":"CITATION70","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"Johnston RJ","year":"2014","unstructured":"Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, Park S. The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer Cell, 2014, 26: 923-937.","journal-title":"Cancer Cell"},{"key":"CITATION71","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","volume":"19","author":"Zhang Q","year":"2018","unstructured":"Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol, 2018, 19: 723-732.","journal-title":"Nat Immunol"},{"key":"CITATION72","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.1158\/0008-5472.CAN-17-0381","volume":"77","author":"He W","year":"2017","unstructured":"He W, Zhang H, Han F, Chen X, Lin R, Wang W, Qiu H. CD155T\/TIGIT signaling regulates CD8+ T-cell metabolism and promotes tumor progression in human gastric cancer. Cancer Res, 2017, 77: 6375-6388.","journal-title":"Cancer Res"},{"key":"CITATION73","doi-asserted-by":"publisher","first-page":"101308","DOI":"10.1016\/j.smim.2019.101308","volume":"42","author":"ElTanbouly MA","year":"2019","unstructured":"ElTanbouly MA, Croteau W, Noelle RJ, Lines JL. VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity. Semin Immunol, 2019, 42: 101308.","journal-title":"Semin Immunol"},{"key":"CITATION74","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.3390\/cells9122691","volume":"9","author":"Lenza MP","year":"2020","unstructured":"Lenza MP, Atxabal U, Oyenarte I, Jim\u00e9nez-Barbero J, Ere\u00f1o-Orbea J. Current status on therapeutic molecules targeting siglec receptors. Cells, 2020, 9: 2691.","journal-title":"Cells"},{"key":"CITATION75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20892\/j.issn.2095-3941.2024.0055","author":"Kong X","year":"2024","unstructured":"Kong X, Zhang J, Chen S, Wang X, Xi Q, Shen H, Zhang R. Immune checkpoint inhibitors: breakthroughs in cancer treatment. Cancer Biol Med, 2024, 1-11.","journal-title":"Cancer Biol Med"},{"key":"CITATION76","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41591-019-0374-x","volume":"25","author":"Wang J","year":"2019","unstructured":"Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med, 2019, 25: 656-666.","journal-title":"Nat Med"},{"key":"CITATION77","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-018-0667-4","volume":"11","author":"Liu F","year":"2018","unstructured":"Liu F, Liu Y, Chen Z. Tim-3 expression and its role in hepatocellular carcinoma. J Hematol Oncol, 2018, 11: 126.","journal-title":"J Hematol Oncol"},{"key":"CITATION78","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/eji.200939842","volume":"40","author":"Anderson AC","year":"2010","unstructured":"Anderson AC, Lord GM, Dardalhon V, Lee DH, Sabatos\u2010Peyton CA, Glimcher LH, Kuchroo VK. T-bet, a Th1 transcription factor regulates the expression of Tim-3. Eur J Immunol, 2010, 40: 859-866.","journal-title":"Eur J Immunol"},{"key":"CITATION79","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/imm.12686","volume":"150","author":"Yi W","year":"2017","unstructured":"Yi W, Zhang P, Liang Y, Zhou Y, Shen H, Fan C, Moorman JP. T-bet-mediated Tim-3 expression dampens monocyte function during chronic hepatitis C virus infection. Immunology, 2017, 150: 301-311.","journal-title":"Immunology"},{"key":"CITATION80","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.1038\/ncomms7072","volume":"6","author":"Zhu C","year":"2015","unstructured":"Zhu C, Sakuishi K, Xiao S, Sun Z, Zaghouani S, Gu G, Wang C. An IL-27\/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nat Commun, 2015, 6: 6072.","journal-title":"Nat Commun"},{"key":"CITATION81","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41419-023-05848-3","volume":"14","author":"Mishra M","year":"2023","unstructured":"Mishra M, Yadav M, Kumar S, Kumar R, Sen P. TIM-3 increases the abundance of type-2 dendritic cells during Leishmania donovani infection by enhancing IL-10 production via STAT3. Cell Death Dis, 2023, 14: 331.","journal-title":"Cell Death Dis"},{"key":"CITATION82","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","volume":"42","author":"Martinez GJ","year":"2015","unstructured":"Martinez GJ, Pereira RM, \u00c4ij\u00f6 T, Kim EY, Marangoni F, Pipkin ME, Togher S. The transcription factor NFAT promotes exhaustion of activated CD8+ T cells. Immunity, 2015, 42: 265-278.","journal-title":"Immunity"},{"key":"CITATION83","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI59806","volume":"122","author":"Yang ZZ","year":"2012","unstructured":"Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, Witzig TE. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest, 2012, 122: 1271-1282.","journal-title":"J Clin Invest"},{"key":"CITATION84","doi-asserted-by":"publisher","first-page":"e0124802","DOI":"10.1371\/journal.pone.0124802","volume":"10","author":"Boivin N","year":"2015","unstructured":"Boivin N, Baillargeon J, Doss PMIA, Roy AP, Rangachari M, Basso AS. Interferon-\u03b2 suppresses murine Th1 cell function in the absence of antigen-presenting cells. PLoS One, 2015, 10: e0124802.","journal-title":"PLoS One"},{"key":"CITATION85","unstructured":"Hakim MS, Jariah ROA, Spaan M, Boonstra A. Interleukin 15 upregulates the expression of PD-1 and TIM-3 on CD4(+) and CD8(+) T cells.  Am J Clin Exp Immunol.  2020, 9: 10-21."},{"key":"CITATION86","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12967-019-1917-0","volume":"17","author":"Zheng Y","year":"2019","unstructured":"Zheng Y, Li Y, Lian J, Yang H, Li F, Zhao S, Qi Y. TNF-\u03b1-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer. J Transl Med, 2019, 17: 165.","journal-title":"J Transl Med"},{"key":"CITATION87","doi-asserted-by":"publisher","first-page":"e179233","DOI":"10.1172\/jci.insight.179233","volume":"9","author":"Zhao SJ","year":"2024","unstructured":"Zhao SJ, Hu XH, Lin XX, Zhang YJ, Wang J, Wang H, Gong GS. IL-27\/Blimp-1 axis regulates the differentiation and function of Tim-3+ Tregs during early pregnancy. JCI Insight, 2024, 9: e179233.","journal-title":"JCI Insight"},{"key":"CITATION88","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nrm2525","volume":"9","author":"Mellman I","year":"2008","unstructured":"Mellman I, Nelson WJ. Coordinated protein sorting, targeting and distribution in polarized cells. Nat Rev Mol Cell Biol, 2008, 9: 833-845.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"CITATION89","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nrm973","volume":"3","author":"Katzmann DJ","year":"2002","unstructured":"Katzmann DJ, Odorizzi G, Emr SD. Receptor downregulation and multivesicular-body sorting. Nat Rev Mol Cell Biol, 2002, 3: 893-905.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"CITATION90","doi-asserted-by":"crossref","unstructured":"Zhu C, Anderson AC, Kuchroo VK. TIM-3 and its regulatory role in immune responses.  Curr Top Microbiol Immunol  2011, 350: 1\u201315.","DOI":"10.1007\/82_2010_84"},{"key":"CITATION91","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4110\/in.2009.9.2.58","volume":"9","author":"Lee MJ","year":"2009","unstructured":"Lee MJ, Heo YM, Hong SH, Kim K, Park S. The binding properties of glycosylated and Non-glycosylated Tim-3 molecules on CD4+CD25+ T cells. Immune Netw, 2009, 9: 58-63.","journal-title":"Immune Netw"},{"key":"CITATION92","doi-asserted-by":"publisher","first-page":"107852","DOI":"10.1016\/j.compbiolchem.2023.107852","volume":"104","author":"Vergoten G","year":"2023","unstructured":"Vergoten G, Bailly C. N-glycosylation reinforces interaction of immune checkpoint TIM-3 with a small molecule ligand. Comput Biol Chem, 2023, 104: 107852.","journal-title":"Comput Biol Chem"},{"key":"CITATION93","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nrm2084","volume":"8","author":"Linder ME","year":"2007","unstructured":"Linder ME, Deschenes RJ. Palmitoylation: policing protein stability and traffic. Nat Rev Mol Cell Biol, 2007, 8: 74-84.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"CITATION94","doi-asserted-by":"publisher","first-page":"eadp7302","DOI":"10.1126\/sciimmunol.adp7302","volume":"9","author":"Zhang Z","year":"2024","unstructured":"Zhang Z, Ren C, Xiao R, Ma S, Liu H, Dou Y, Fan Y. Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity. Sci Immunol, 2024, 9: eadp7302.","journal-title":"Sci Immunol"},{"key":"CITATION95","doi-asserted-by":"publisher","first-page":"e00971","DOI":"10.1002\/advs.202500971","volume":"12","author":"Cui L","year":"2025","unstructured":"Cui L, Meng X, Luo Y, Qian J, Sun F, Qiu M, Wang S. Dysfunctional decidual CD4+ T cells induce recurrent pregnancy loss via palmitoylation-dependent Tim-3 lysosomal sorting and degradation. Adv Sci, 2025, 12: e00971.","journal-title":"Adv Sci"},{"key":"CITATION96","unstructured":"Manandhar P, Landy E, Mori K, Kane LP. Tim-3 promotes early differentiation of Tbet+ effector T cells during acute viral infection.  bioRxiv  2025: 2025.2007.2008.663709."},{"key":"CITATION97","doi-asserted-by":"publisher","first-page":"14733","DOI":"10.1073\/pnas.1009731107","volume":"107","author":"Jin HT","year":"2010","unstructured":"Jin HT, Anderson AC, Tan WG, West EE, Ha SJ, Araki K, Freeman GJ. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA, 2010, 107: 14733-14738.","journal-title":"Proc Natl Acad Sci USA"},{"key":"CITATION98","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","volume":"117","author":"Zhou Q","year":"2011","unstructured":"Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood, 2011, 117: 4501-4510.","journal-title":"Blood"},{"key":"CITATION99","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1158\/0008-5472.CAN-13-2908","volume":"74","author":"Fourcade J","year":"2014","unstructured":"Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines. Cancer Res, 2014, 74: 1045-1055.","journal-title":"Cancer Res"},{"key":"CITATION100","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00345-015-1656-7","volume":"34","author":"Cai C","year":"2016","unstructured":"Cai C, Xu YF, Wu ZJ, Dong Q, Li MY, Olson JC, Rabinowitz YM. Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma. World J Urol, 2016, 34: 561-567.","journal-title":"World J Urol"},{"key":"CITATION101","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1172\/JCI45138","volume":"122","author":"Gupta S","year":"2012","unstructured":"Gupta S, Thornley TB, Gao W, Larocca R, Turka LA, Kuchroo VK, Strom TB. Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs. J Clin Invest, 2012, 122: 2395-2404.","journal-title":"J Clin Invest"},{"key":"CITATION102","doi-asserted-by":"publisher","first-page":"e30676","DOI":"10.1371\/journal.pone.0030676","volume":"7","author":"Gao X","year":"2012","unstructured":"Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One, 2012, 7: e30676.","journal-title":"PLoS One"},{"key":"CITATION103","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13046-018-0713-7","volume":"37","author":"Liu JF","year":"2018","unstructured":"Liu JF, Wu L, Yang LL, Deng WW, Mao L, Wu H, Zhang WF. Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer. J Exp Clin Cancer Res, 2018, 37: 44.","journal-title":"J Exp Clin Cancer Res"},{"key":"CITATION104","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/cmi.2014.126","volume":"13","author":"Li YH","year":"2016","unstructured":"Li YH, Zhou WH, Tao Y, Wang SC, Jiang YL, Zhang D, Piao HL. The Galectin-9\/Tim-3 pathway is involved in the regulation of NK cell function at the maternal\u2013fetal interface in early pregnancy. Cell Mol Immunol, 2016, 13: 73-81.","journal-title":"Cell Mol Immunol"},{"key":"CITATION105","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3389\/fimmu.2013.00449","volume":"4","author":"Han G","year":"2013","unstructured":"Han G, Chen G, Shen B, Li Y. Tim-3: an activation marker and activation limiter of innate immune cells. Front Immunol, 2013, 4: 449.","journal-title":"Front Immunol"},{"key":"CITATION106","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1158\/2326-6066.CIR-13-0171","volume":"2","author":"da Silva IP","year":"2014","unstructured":"da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK, Osman I. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res, 2014, 2: 410-422.","journal-title":"Cancer Immunol Res"},{"key":"CITATION107","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2012.02.009","volume":"222","author":"Hou N","year":"2012","unstructured":"Hou N, Zhao D, Liu Y, Gao L, Liang X, Liu X, Gai X. Increased expression of T cell immunoglobulin- and mucin domain-containing molecule-3 on natural killer cells in atherogenesis. Atherosclerosis, 2012, 222: 67-73.","journal-title":"Atherosclerosis"},{"key":"CITATION108","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","volume":"30","author":"Roberts EW","year":"2016","unstructured":"Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, Kaisho T. Critical role for CD103+\/CD141+ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell, 2016, 30: 324-336.","journal-title":"Cancer Cell"},{"key":"CITATION109","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","volume":"50","author":"Zilionis R","year":"2019","unstructured":"Zilionis R, Engblom C, Pfirschke C, Savova V, Zemmour D, Saatcioglu HD, Krishnan I. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity, 2019, 50: 1317-1334.e10.","journal-title":"Immunity"},{"key":"CITATION110","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmet.2019.02.007","volume":"23","author":"Yang H","year":"2019","unstructured":"Yang H, Xie T, Li D, Du X, Wang T, Li C, Song X. Tim-3 aggravates podocyte injury in diabetic nephropathy by promoting macrophage activation via the NF-\u03baB\/TNF-\u03b1 pathway. Mol Metab, 2019, 23: 24-36.","journal-title":"Mol Metab"},{"key":"CITATION111","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1189\/jlb.1010591","volume":"91","author":"Zhang Y","year":"2012","unstructured":"Zhang Y, Ma CJ, Wang JM, Ji XJ, Wu XY, Moorman JP, Yao ZQ. Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes. J Leukoc Biol, 2012, 91: 189-196.","journal-title":"J Leukoc Biol"},{"key":"CITATION112","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.4049\/jimmunol.1202661","volume":"190","author":"Yang X","year":"2013","unstructured":"Yang X, Jiang X, Chen G, Xiao Y, Geng S, Kang C, Zhou T. T cell Ig Mucin-3 promotes homeostasis of sepsis by negatively regulating the TLR response. J Immunol, 2013, 190: 2068-2079.","journal-title":"J Immunol"},{"key":"CITATION113","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.clim.2015.07.008","volume":"160","author":"Jiang X","year":"2015","unstructured":"Jiang X, Yu J, Shi Q, Xiao Y, Wang W, Chen G, Zhao Z. Tim-3 promotes intestinal homeostasis in DSS colitis by inhibiting M1 polarization of macrophages. Clin Immunol, 2015, 160: 328-335.","journal-title":"Clin Immunol"},{"key":"CITATION114","doi-asserted-by":"publisher","first-page":"e1211219","DOI":"10.1080\/2162402X.2016.1211219","volume":"5","author":"Jiang X","year":"2016","unstructured":"Jiang X, Zhou T, Xiao Y, Yu J, Dou S, Chen G, Wang R. Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis. OncoImmunology, 2016, 5: e1211219.","journal-title":"OncoImmunology"},{"key":"CITATION115","doi-asserted-by":"publisher","first-page":"eabl5165","DOI":"10.1126\/sciadv.abl5165","volume":"8","author":"Ni X","year":"2022","unstructured":"Ni X, Wu W, Sun X, Ma J, Yu Z, He X, Cheng J. Interrogating glioma-M2 macrophage interactions identifies Gal-9\/Tim-3 as a viable target against PTEN-null glioblastoma. Sci Adv, 2022, 8: eabl5165.","journal-title":"Sci Adv"},{"key":"CITATION116","doi-asserted-by":"publisher","first-page":"42095","DOI":"10.1038\/srep42095","volume":"7","author":"Wang Z","year":"2017","unstructured":"Wang Z, Sun D, Chen G, Li G, Dou S, Wang R, Xiao H. Tim-3 inhibits macrophage control of Listeria monocytogenes by inhibiting Nrf2. Sci Rep, 2017, 7: 42095.","journal-title":"Sci Rep"},{"key":"CITATION117","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41423-018-0032-0","volume":"16","author":"Du X","year":"2019","unstructured":"Du X, Wu Z, Xu Y, Liu Y, Liu W, Wang T, Li C. Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice. Cell Mol Immunol, 2019, 16: 878-886.","journal-title":"Cell Mol Immunol"},{"key":"CITATION118","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1182\/blood-2006-11-058800","volume":"110","author":"Nakae S","year":"2007","unstructured":"Nakae S, Iikura M, Suto H, Akiba H, Umetsu DT, DeKruyff RH, Saito H. TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells. Blood, 2007, 110: 2565-2568.","journal-title":"Blood"},{"key":"CITATION119","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1084\/jem.20150388","volume":"212","author":"Phong BL","year":"2015","unstructured":"Phong BL, Avery L, Sumpter TL, Gorman JV, Watkins SC, Colgan JD, Kane LP. Tim-3 enhances Fc\u03b5RI-proximal signaling to modulate mast cell activation. J Exp Med, 2015, 212: 2289-2304.","journal-title":"J Exp Med"},{"key":"CITATION120","doi-asserted-by":"publisher","first-page":"640","DOI":"10.4049\/jimmunol.1601150","volume":"198","author":"Phong B","year":"2017","unstructured":"Phong B, Avery L, Menk AV, Delgoffe GM, Kane LP. Cutting edge: murine mast cells rapidly modulate metabolic pathways essential for distinct effector functions. J Immunol, 2017, 198: 640-644.","journal-title":"J Immunol"},{"key":"CITATION121","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3892\/ol.2013.1410","volume":"6","author":"Shang Y","year":"2013","unstructured":"Shang Y, Li Z, Li H, Xia H, Lin Z. TIM-3 expression in human osteosarcoma: correlation with the expression of epithelial-mesenchymal transition-specific biomarkers. Oncol Lett, 2013, 6: 490-494.","journal-title":"Oncol Lett"},{"key":"CITATION122","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1038\/s41388-018-0140-4","volume":"37","author":"Zhang H","year":"2018","unstructured":"Zhang H, Song Y, Yang H, Liu Z, Gao L, Liang X, Ma C. Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-\u03baB\/IL-6\/STAT3 axis. Oncogene, 2018, 37: 2456-2468.","journal-title":"Oncogene"},{"key":"CITATION123","doi-asserted-by":"publisher","first-page":"564","DOI":"10.21147\/j.issn.1000-9604.2020.05.02","volume":"32","author":"Cong Y","year":"2020","unstructured":"Cong Y, Cui Y, Zhu S, Cao J, Zou H, A. Martin T, Qiao G. Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF-\u03baB\/STAT3 signalling pathway in breast cancer cells. Chin J Cancer Res, 2020, 32: 564-579.","journal-title":"Chin J Cancer Res"},{"key":"CITATION124","doi-asserted-by":"publisher","first-page":"882","DOI":"10.4103\/jcrt.JCRT_630_18","volume":"15","author":"Zhang J","year":"2019","unstructured":"Zhang J, Zhu ZQ, Li YX, Zhuang QF, Lai Y, Li SF, Xu XB. Tim-3 expression in glioma cells is associated with drug resistance. J Can Res Ther, 2019, 15: 882-888.","journal-title":"J Can Res Ther"},{"key":"CITATION125","doi-asserted-by":"publisher","first-page":"105329","DOI":"10.1016\/j.isci.2022.105329","volume":"25","author":"Guo Q","year":"2022","unstructured":"Guo Q, Shen S, Guan G, Zhu C, Zou C, Cao J, Cheng W. Cancer cell intrinsic TIM-3 induces glioblastoma progression. iScience, 2022, 25: 105329.","journal-title":"iScience"},{"key":"CITATION126","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1158\/0008-5472.CAN-22-0970","volume":"82","author":"Schatton T","year":"2022","unstructured":"Schatton T, Itoh Y, Martins C, Rasbach E, Singh P, Silva M, Mucciarone K. Inhibition of melanoma cell\u2013intrinsic Tim-3 stimulates MAPK-dependent tumorigenesis. Cancer Res, 2022, 82: 3774-3784.","journal-title":"Cancer Res"},{"key":"CITATION127","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1080\/10428194.2021.1984454","volume":"63","author":"Chajuwan T","year":"2022","unstructured":"Chajuwan T, Kansuwan P, Kobbuaklee S, Chanswangphuwana C. Characteristics and clinical correlation of TIM-3 and PD-1\/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia. Leukemia Lymphoma, 2022, 63: 450-456.","journal-title":"Leukemia Lymphoma"},{"key":"CITATION128","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.lungcan.2018.04.009","volume":"121","author":"Su H","year":"2018","unstructured":"Su H, Xie H, Dai C, Ren Y, She Y, Xu L, Chen D. Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma. Lung Cancer, 2018, 121: 18-24.","journal-title":"Lung Cancer"},{"key":"CITATION129","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ygyno.2020.07.012","volume":"159","author":"Wu JL","year":"2020","unstructured":"Wu JL, Zhao J, Zhang HB, Zuo WW, Li Y, Kang S. Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer. Gynecol Oncol, 2020, 159: 270-276.","journal-title":"Gynecol Oncol"},{"key":"CITATION130","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.21037\/jtd-23-227","volume":"15","author":"Zhang C","year":"2023","unstructured":"Zhang C, Xu L, Ma Y, Huang Y, Zhou L, Le H, Chen Z. Increased TIM-3 expression in tumor-associated macrophages predicts a poorer prognosis in non-small cell lung cancer: a retrospective cohort study. J Thorac Dis, 2023, 15: 1433-1444.","journal-title":"J Thorac Dis"},{"key":"CITATION131","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","volume":"71","author":"Ngiow SF","year":"2011","unstructured":"Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MWL, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-\u03b3-mediated antitumor immunity and suppresses established tumors. Cancer Res, 2011, 71: 3540-3551.","journal-title":"Cancer Res"},{"key":"CITATION132","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.ccell.2023.09.001","volume":"41","author":"Ausejo-Mauleon I","year":"2023","unstructured":"Ausejo-Mauleon I, Labiano S, de la Nava D, Laspidea V, Zalacain M, Marrod\u00e1n L, Garc\u00eda-Moure M. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer Cell, 2023, 41: 1911-1926.e8.","journal-title":"Cancer Cell"},{"key":"CITATION133","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","volume":"7","author":"Koyama S","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun, 2016, 7: 10501.","journal-title":"Nat Commun"},{"key":"CITATION134","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2023.144","author":"Ruff SM","year":"2024","unstructured":"Ruff SM, Pawlik TM. Emerging data on immune checkpoint inhibitors in the neoadjuvant and adjuvant setting for patients with hepatocellular carcinoma. Hepatoma Res, 2024.","journal-title":"Hepatoma Res"},{"key":"CITATION135","doi-asserted-by":"crossref","unstructured":"Ruff SM, Pawlik TM. The role of immune checkpoint inhibitors and\/or Yttrium-90 radioembolization in the management of hepatocellular carcinoma: challenges of treatment sequence.  Hepatoma Research  2024.","DOI":"10.20517\/2394-5079.2024.59"},{"key":"CITATION136","doi-asserted-by":"crossref","unstructured":"Arvanitakis K, Papadakos SP, Vakadaris G, Chatzikalil E, Stergiou IE, Kalopitas G, Theocharis S, et al. Shedding light on the role of LAG-3 in hepatocellular carcinoma: unraveling immunomodulatory pathways.  Hepatoma Research  2024.","DOI":"10.20517\/2394-5079.2024.36"},{"key":"CITATION137","doi-asserted-by":"publisher","first-page":"eadg6752","DOI":"10.1126\/scitranslmed.adg6752","volume":"15","author":"Ma S","year":"2023","unstructured":"Ma S, Tian Y, Peng J, Chen C, Peng X, Zhao F, Li Z. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell\u2013mediated antitumor immunotherapy in preclinical mouse models. Sci Transl Med, 2023, 15: eadg6752.","journal-title":"Sci Transl Med"},{"key":"CITATION138","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1158\/2326-6066.CIR-14-0039","volume":"2","author":"Anderson AC","year":"2014","unstructured":"Anderson AC. Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol Res, 2014, 2: 393-398.","journal-title":"Cancer Immunol Res"},{"key":"CITATION139","doi-asserted-by":"publisher","first-page":"6393","DOI":"10.1158\/1078-0432.CCR-21-0261","volume":"27","author":"Hollebecque A","year":"2021","unstructured":"Hollebecque A, Chung HC, de Miguel MJ, Italiano A, Machiels JP, Lin CC, Dhani NC. Safety and antitumor activity of \u03b1-PD-L1 antibody as monotherapy or in combination with \u03b1-TIM-3 antibody in patients with microsatellite instability-high\/mismatch repair-deficient tumors. Clin Cancer Res, 2021, 27: 6393-6404.","journal-title":"Clin Cancer Res"},{"key":"CITATION140","doi-asserted-by":"publisher","first-page":"14757","DOI":"10.1021\/acs.jmedchem.1c01336","volume":"64","author":"Rietz TA","year":"2021","unstructured":"Rietz TA, Teuscher KB, Mills JJ, Gogliotti RD, Lepovitz LT, Scaggs WR, Yoshida K. Fragment-based discovery of small molecules bound to T-cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3). J Med Chem, 2021, 64: 14757-14772.","journal-title":"J Med Chem"},{"key":"CITATION141","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1021\/jacs.1c11498","volume":"144","author":"Yang X","year":"2022","unstructured":"Yang X, Li M, Qin X, Tan S, Du L, Ma C, Li M. Photophosphatidylserine guides natural killer cell photoimmunotherapy via Tim-3. J Am Chem Soc, 2022, 144: 3863-3874.","journal-title":"J Am Chem Soc"},{"key":"CITATION142","doi-asserted-by":"publisher","first-page":"e003176","DOI":"10.1136\/jitc-2021-003176","volume":"9","author":"Zhao S","year":"2021","unstructured":"Zhao S, Wang C, Lu P, Lou Y, Liu H, Wang T, Yang S. Switch receptor T3\/28 improves long-term persistence and antitumor efficacy of CAR-T cells. J Immunother Cancer, 2021, 9: e003176.","journal-title":"J Immunother Cancer"},{"key":"CITATION143","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/S0959-8049(16)32903-3","volume":"69","author":"Murtaza A","year":"2016","unstructured":"Murtaza A, Laken H, Da Silva Correia J, McNeeley P, Altobell L, Zhang J, Vancutsem P. Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody. Eur J Cancer, 2016, 69: S102.","journal-title":"Eur J Cancer"},{"key":"CITATION144","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","volume":"20","author":"Andrews LP","year":"2019","unstructured":"Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol, 2019, 20: 1425-1434.","journal-title":"Nat Immunol"},{"key":"CITATION145","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","volume":"27","author":"Curigliano G","year":"2021","unstructured":"Curigliano G, Gelderblom H, Mach N, Doi T, Tai D, Forde PM, Sarantopoulos J. Phase I\/Ib clinical trial of sabatolimab, an Anti-TIM-3 antibody, alone and in combination with spartalizumab, an Anti-PD-1 antibody, in advanced solid tumors. Clin Cancer Res, 2021, 27: 3620-3629.","journal-title":"Clin Cancer Res"},{"key":"CITATION146","doi-asserted-by":"publisher","first-page":"E32","DOI":"10.1002\/ajh.27161","volume":"99","author":"Brunner AM","year":"2024","unstructured":"Brunner AM, Esteve J, Porkka K, Knapper S, Traer E, Scholl S, Garcia\u2010Manero G. Phase Ib study of sabatolimab (MBG453 ), a novel immunotherapy targetingTIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol, 2024, 99: E32.","journal-title":"Am J Hematol"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/D2A0AF2CA2D84F018FB6BA96E336C3D6","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025235","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/D2A0AF2CA2D84F018FB6BA96E336C3D6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T08:35:57Z","timestamp":1769675757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":146,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,24]]},"published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.3724\/abbs.2025235","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,24]]}}}